After some delays due to the COVID-19 pandemic, the Phase 2/3 clinical trial evaluating whether Mavenclad (cladribine) can slow hand and arm function worsening in adults with progressive multiple sclerosis (MS) and very limited walking abilities, has recruited its first patient. The study, ChariotMS (NCT04695080), aims to…
advanced MS
An upcoming Phase 2 clinical trial, called ChariotMS, will test whether Mavenclad (cladribine) can slow a worsening of hand and arm function in people with progressive multiple sclerosis (MS) and very limited walking abilities. Patients reliant on wheelchairs or aids to walk even short distances generally have…
In the brains of people with advanced multiple sclerosis (MS), memory immune cells reside in the brain tissue rather than entering through the bloodstream, a new study suggests. The study, “Tissue-resident memory T cells invade the brain parenchyma in multiple sclerosis white matter lesions,” was published…
Specialist inpatient rehabilitation is a cost-effective strategy that can improve the clinical outcomes of patients with multiple sclerosis (MS), particularly those at more advanced stages of the disease, a study in the United Kingdom (U.K.) found. The study, “Cost-efficiency of specialist inpatient rehabilitation for adults with…
Healthcare specialists for multiple sclerosis patients in the U.K. with advanced disease and challenging needs are getting support and recognition through a new program from the MS Trust. Called the Advanced MS Champions Programme, it will recognize six MS specialist “champions” working with people with advanced MS, and their families…
Helius Medical Technologies announced results of a pilot study, demonstrating the benefits of PoNS Therapy — a combination of the investigational Portable Neuromodulation Stimulator (PoNS) device with physical therapy — in patients with advanced multiple sclerosis (MS). Specifically, the treatment was seen to improve both patients’ quality of life, and physical and…